As filed with the Securities and Exchange Commission on March 23, 2023.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Finch Therapeutics Group, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
82-3433558 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification Number) |
200 Inner Belt Road, Suite 400
Somerville, Massachusetts 02143
(617) 229-6499
(Address of principal executive offices) (Zip code)
Finch Therapeutics Group, Inc. 2021 Equity Incentive Plan
Finch Therapeutics Group, Inc. 2021 Employee Stock Purchase Plan
(Full titles of the plans)
Mark Smith, Ph.D.
Chief
Executive Officer
Finch Therapeutics Group, Inc.
200 Inner Belt Road, Suite 400
Somerville, Massachusetts 02143
(617) 229-6499
(Name, address and telephone number, including area code, of agent for service)
Copies to:
Marc
Rubenstein
William Michener
Ropes & Gray LLP
Prudential Tower
800
Boylston Street
Boston, MA 02199-3600
(617) 951-7000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐